ArisGlobal LifeSphere NavaX AI Integration & Pharmacovigilance Automation

NavaX is ArisGlobal's cognitive computing engine — a platform-native fabric of generative AI and agentic AI that operates across every LifeSphere module, not a bolt-on add-on. Unlike document-extraction tools that sit beside a pharmacovigilance database, NavaX performs end-to-end reasoning: it interprets regulatory guidelines, converts them into structured rule checklists, validates dossiers, generates narratives, detects signals, and orchestrates multi-step workflows. ArisGlobal reports NavaX drives up to 65% efficiency gains in case intake, 90% extraction accuracy, 50% efficiency improvements across safety and regulatory workflows, and over 100 hours saved on manual regulatory workflows. The platform processes more than 1 million safety cases with projected volume reaching 2.5 million by mid-2026. Compared to Oracle Safety One Intake (document-to-field extraction) or Veeva Vault Safety's narrower AI scope, NavaX extends further into narrative generation, signal reasoning, translation, and regulatory intelligence. IntuitionLabs configures NavaX extraction rules, validates AI accuracy against manual processing benchmarks, and extends the native capabilities with custom agents that encode organization-specific medical writing conventions, coding preferences, and operational policies.

ArisGlobal launched a new generation of NavaX-powered agents in 2025-2026 that apply agentic AI to specific life sciences workflows. Intelligence Agents automatically interpret regulatory guidelines from health authorities (FDA, EMA, PMDA, national competent authorities), convert them into precise rule checklists, and assess dossiers from LifeSphere Submissions with clear compliance evaluations. This automates what has traditionally been a highly manual regulatory intelligence function staffed by senior regulatory affairs professionals. Distribution Agents deliver continuous compliance validation by consuming evolving regulatory guidelines, validating them against internal distribution logic, and triggering governed change workflows when discrepancies arise — for example, when a new EMA labeling requirement must be reflected in internal label templates across multiple markets. Signals Agents is an intelligent assistant that interprets user intent, determines the best analytical approach, and dynamically plans and executes signal evaluation workflows using reasoning-based orchestration spanning safety data, analytics, and expert judgment. IntuitionLabs configures these agents for client-specific regulatory footprints, builds prompt templates that capture organizational policies, and integrates the agent outputs with downstream human review workflows that satisfy ICH E2D and GVP medical review requirements.

NavaX Translation, launched in February 2026 and generally available to LifeSphere Safety customers from July 2026, embeds certified pharma-grade translation directly into LifeSphere Safety workflows. This addresses a major operational bottleneck: global pharmacovigilance requires adverse event reports from 20+ countries to be translated into English for EMA and FDA submissions, as well as into local languages for national health authorities. Traditional medical translation services add cost and cycle-time, and lower-quality AI translation introduces safety risk because a mistranslation of clinical text could change the meaning of an adverse event description. NavaX Translation is specifically tuned for medical terminology and pharmacovigilance conventions, with coverage across major global languages. IntuitionLabs extends the native capability with custom translation quality assurance workflows: AI models that verify terminology against approved medical dictionaries, automated detection of translation errors that could affect adverse event assessment, and integration with MedDRA multilingual term databases. For organizations processing cases from 20+ countries, AI translation reduces case processing cycle times significantly while maintaining the translation accuracy that regulatory submissions demand.

AI-assisted MedDRA coding is one of the most impactful automation opportunities in pharmacovigilance case processing, and NavaX includes native coding assistance that IntuitionLabs extends with organization-specific intelligence. MedDRA coding requires trained safety associates to interpret adverse event descriptions — often written in colloquial language by patients or in varied clinical terminology by healthcare professionals — and map them to the appropriate terms in MedDRA's five-level hierarchy: System Organ Class (SOC), High Level Group Term (HLGT), High Level Term (HLT), Preferred Term (PT), and Lowest Level Term (LLT). The consistency challenge is significant: the same adverse event described differently ("felt dizzy," "vertigo," "room spinning," "lightheadedness") should map to the correct MedDRA term consistently across thousands of cases. AI models analyze verbatim adverse event text and suggest appropriate MedDRA terms with confidence scores, presenting options to the human coder who makes the final selection. IntuitionLabs trains models on your historical coding decisions to learn your organization's conventions, handling straightforward codings autonomously (with verification) while flagging ambiguous cases for expert medical judgment. This reduces coding time by 40-60% while improving consistency, which directly improves the quality of downstream signal detection analyses that depend on accurate, consistent MedDRA coding.

Every safety case in LifeSphere requires a medical narrative — a structured free-text summary that describes the adverse event in clinical context. Experienced safety associates spend 15-30 minutes per narrative synthesizing patient demographics, medical history, suspect medications, event details, treatment, and outcome into a coherent clinical description. For organizations processing hundreds or thousands of cases monthly, narrative writing is a significant operational bottleneck. NavaX generates draft narratives natively, but the default templates are generic; IntuitionLabs tunes narrative generation to your organization's specific medical writing conventions, terminology preferences, and formatting standards by training models on your historical approved narratives. The AI-generated draft is presented to a qualified safety associate or medical reviewer who verifies accuracy, adds clinical interpretation, and approves the final narrative — the human-in-the-loop approach maintains ICH E2D qualified review requirements while reducing narrative writing time by 60-80%. For follow-up cases, the AI generates narrative amendments that append new information in the correct structure without rewriting existing approved content. Every AI-generated output is logged with model version, input data references, and reviewer identity per 21 CFR Part 11 electronic record requirements.

AI in pharmacovigilance operates in one of the most heavily regulated domains in healthcare, requiring controls beyond standard enterprise AI governance. IntuitionLabs implements a comprehensive compliance framework for every LifeSphere AI integration. Audit trail requirements: every AI output (narrative drafts, coding suggestions, triage decisions, regulatory assessments) is logged with timestamps, model version, input data references, and reviewer identity per 21 CFR Part 11 and EU Annex 11 electronic record requirements. Human-in-the-loop: all AI outputs must be reviewed and approved by qualified personnel before becoming part of the regulatory record — no fully autonomous case processing. Data privacy: patient data processed by AI models must comply with GDPR, HIPAA, and EMA GVP Module VI personal data protection. Model validation: AI components are validated per GAMP 5 Category 5 (Custom Applications) with documented performance metrics, accuracy benchmarks against manual processing, and periodic revalidation. Explainability: AI coding suggestions and triage decisions must be traceable so qualified reviewers can evaluate the AI's reasoning.

Yes — literature surveillance is regulated under EMA GVP Module VI and FDA post-marketing safety reporting guidance, which require Marketing Authorization Holders to monitor published medical literature for adverse event reports related to their products. LifeSphere Literature Intelligence is ArisGlobal's native module that automates the screening, extraction, and case entry steps. The AI monitors configured search queries across PubMed, Embase, and other medical databases on defined schedules, classifies articles by relevance to your product portfolio, extracts adverse event information from published text (patient details, medications, events, outcomes), and generates draft LifeSphere case entries that medical reviewers approve. IntuitionLabs extends Literature Intelligence with custom configuration tuned to your product portfolio: relevance classification thresholds, language coverage for regional journals, integration with ClinicalTrials.gov publication tracking, and audit trail documentation showing inspection-ready evidence that your surveillance program is comprehensive and systematic. This is a critical compliance safeguard because missed articles become regulatory inspection findings.

Traditional case triage operates on simple rules: cases are prioritized by receipt date and regulatory deadline, with serious/unexpected cases flagged for expedited processing. This treats all serious cases equally regardless of clinical significance. AI case triage analyzes incoming cases and prioritizes them based on multiple factors: Clinical urgency — cases involving death, life-threatening events, hospitalization, or significant disability escalate above routine serious cases. Signal relevance — cases involving adverse events under active signal evaluation receive higher priority. Regulatory complexity — cases requiring submission to multiple health authorities or involving REMS products are flagged for specialized processing. Data quality — cases with sufficient information for meaningful medical assessment are prioritized over poorly documented reports that will require follow-up. Pattern detection — AI identifies clusters of similar cases that may represent an emerging safety signal, escalating individual cases that are part of a larger pattern. IntuitionLabs builds these triage models on top of your LifeSphere case data, training on historical processing patterns and medical review decisions. The AI triage score supplements existing LifeSphere workflow routing, adding a clinical intelligence layer that helps pharmacovigilance teams allocate medical review resources to the cases that matter most for patient safety.

The Model Context Protocol (MCP) is an open standard developed by Anthropic that enables AI assistants to securely connect to external data sources and tools through a standardized, auditable interface. An MCP server for ArisGlobal LifeSphere would expose pharmacovigilance and regulatory operations as structured tools that AI models like Claude can invoke, providing a controlled channel for AI to interact with safety and regulatory data beyond what NavaX handles natively. IntuitionLabs builds custom MCP servers that wrap LifeSphere REST APIs and expose domain-relevant operations: querying case data by product, event, or date range; retrieving case narratives and medical assessments; looking up MedDRA coding hierarchies; checking regulatory submission status; pulling commitments from LifeSphere RIM; and accessing signal detection results. Every MCP tool invocation is logged with full audit trail — who requested the data, what query was executed, what data was returned, and when. Access controls are enforced at the MCP server layer so the AI can only access data the requesting user is authorized to view. MCP standardizes the AI interaction pattern across all data sources (LifeSphere, Veeva, EDC systems, Snowflake), reduces custom integration code, and provides a natural point for implementing compliance controls like PII filtering and access logging.

Traditional safety signal detection in LifeSphere Advanced Signals relies on disproportionality analysis — statistical methods (PRR, ROR, MGPS) that compare observed vs. expected adverse event reporting frequencies. While these methods are validated and regulatory-accepted, they have limitations: they require sufficient case volume to generate meaningful statistics, they operate on structured MedDRA-coded data only (ignoring free-text narrative content), and they generate large numbers of statistical signals that require manual medical review to separate clinically meaningful signals from statistical noise. NavaX Signals Agents and custom AI enhance signal detection in several complementary ways. Narrative-based detection — AI analyzes free-text case narratives to identify clinical patterns structured coding may miss: specific symptom combinations, temporal relationships, dose-response patterns described in text. Cross-source correlation — AI correlates LifeSphere case data with external sources including ClinicalTrials.gov safety data, published literature, and real-world data to identify converging evidence. Signal prioritization — AI ranks detected signals by clinical significance using biological plausibility, mechanistic coherence with the drug's pharmacology, consistency across data sources, and similarity to known drug class effects. IntuitionLabs builds these AI capabilities as complementary layers on top of validated statistical methods, ensuring regulatory-accepted approaches remain the foundation while AI adds clinical intelligence to signal evaluation.

AI integration with LifeSphere delivers measurable returns across multiple dimensions of pharmacovigilance and regulatory operations. Case processing efficiency: NavaX Advanced Intake reduces manual data entry by the majority of per-case effort. AI narrative generation reduces narrative writing time by 60-80%. AI-assisted MedDRA coding reduces coding time by 40-60%. For an organization processing 5,000 cases per month, these efficiencies save 15,000-25,000 person-hours annually. Quality improvement: AI coding assistance improves consistency, which directly improves signal detection accuracy. AI-generated narratives follow standardized templates consistently, reducing quality review rejection rates. Automated literature surveillance eliminates the risk of missed articles that can become regulatory inspection findings. Compliance risk reduction: AI case triage ensures high-priority cases are processed within regulatory deadlines, reducing the risk of late submissions that can trigger FDA warning letters. Regulatory intelligence: Intelligence Agents continuously monitor health authority guideline updates, ensuring your dossiers remain aligned with evolving expectations. Scalability: AI enables teams to handle growing case volumes without proportional headcount increases — critical as post-marketing surveillance obligations expand. Typical ROI timelines are 6-12 months from deployment.